for the Period Ended 31 October 2024
| Profit and loss | |
| Balance sheet | |
| Additional notes | |
| Balance sheet notes | |
| Community Interest Report |
for the Period Ended
| 2024 | 2023 | |
|---|---|---|
|
|
£ |
£ |
| Turnover: |
|
|
| Gross profit(or loss): |
|
|
| Administrative expenses: |
(
|
(
|
| Operating profit(or loss): |
|
|
| Profit(or loss) before tax: |
|
|
| Profit(or loss) for the financial year: |
|
|
As at
| Notes | 2024 | 2023 | |
|---|---|---|---|
|
|
£ |
£ |
|
| Current assets | |||
| Cash at bank and in hand: |
|
|
|
| Total current assets: |
|
|
|
| Creditors: amounts falling due within one year: | 3 |
(
|
(
|
| Net current assets (liabilities): |
|
( |
|
| Total assets less current liabilities: |
|
( |
|
| Total net assets (liabilities): |
|
( |
|
| Members' funds | |||
| Profit and loss account: |
|
( |
|
| Total members' funds: |
|
( |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 October 2024
Basis of measurement and preparation
for the Period Ended 31 October 2024
| 2024 | 2023 | |
|---|---|---|
| Average number of employees during the period |
|
|
for the Period Ended 31 October 2024
| 2024 | 2023 | |
|---|---|---|
| £ | £ | |
| Other creditors |
|
|
| Total |
|
|
for the Period Ended 31 October 2024
| Name of director receiving advance or credit: |
|
| Description of the transaction: | |
|
|
|
| £ | |
|---|---|
| Balance at 31 October 2023 |
|
| Advances or credits made: | |
| Advances or credits repaid: | |
| Balance at 31 October 2024 |
|
During this year the Company agreed it first commercial license with a Uk company and it continues to support its open source PROforma implementation , as can be seen at Https://gitlab.com/openclinical. It also participated in three UK funded research projects and looks forward to the trialling of a destination decision support system for the Ambulance service in Rwanda and the further development of CDSS to support care for patients with multimorbidity in Sri Lanka.
The company's stakeholders are global health technology and publishing and other entities including government agencies and care providers and professionals. Stakeholders are engaged and consulted via publications and demonstrations and the provision of the OpenClinical open access and open source repositories.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
31 May 2025
And signed on behalf of the board by:
Name: Dr Matthew South
Status: Director